National Cancer Institute

August 11, 2026

HLA Protein Technologies’ New NCI License Speeds TCR Immunotherapy and Oncology Discovery

OKLAHOMA CITY, Okla. — HLA Protein Technologies, Inc. (formerly Pure Protein, LLC), a global leader in soluble, natively folded HLA proteins and custom peptide binding services, announced a major step forward for TCR research. The Company has secured an internal use license from the National Cancer Institute (NCI), a component of the National Institutes of Health (NIH), covering advanced T-cell receptor (TCR) compositions and methods….